Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

@article{Schneider2010AbusedeterrentAT,
  title={Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?},
  author={Jennifer P. Schneider and Michele L Matthews and Robert N. Jamison},
  journal={CNS drugs},
  year={2010},
  volume={24 10},
  pages={805-10}
}
About one in every three individuals will experience chronic pain in their lifetime, and opioids are known to be an effective means to treat this condition. Much attention, however, has been given to the fact that prescription opioid analgesics are some of the most frequently abused drugs, and misuse is prominent in patients with chronic pain. Several new opioid formulations that are designed to prevent or deter the abuse of opioids are currently in development, and two have been approved for… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Prescribing trends for opioids, benzodiazepines, amphetamines, and barbiturates from 1998-2007: US Public Health Service [online

S. Belouin
Available from URL: http:// nac.samhsa.gov/DTAB/ [Accessed 2010 Jul • 2010

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

The journal of pain : official journal of the American Pain Society • 2009

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or case of extraction

HG White AG. Bimbaum, DB Roth
Appl Health Econ Health Policy • 2009

Abuse deterrence focus of upcoming opioid formulations.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2008

Abuse-deterrent properties and pharmacokinetics of a novel sustained release formulation of oxyeodone for the treatment of moderate to severe pain [abstract

A Fleming, P Noonan, A. Wheeler
J Pain • 2008

Efficacy and safety evaluation of an extended-release morphine sulfate formulation with sequestered naltrexone for the treatment of osteoarthritis [abstract

N Katz, S Sun, L Fox
J Pain • 2008

Evaluation for flushing, safety, and tolerability of niacin in combination with 40 mg oxyeodone combination with 40 mg oxyeodone [abstract

DR Jasinski
Clin Pharmacol Ther 2008 Apr • 2008

Similar Papers

Loading similar papers…